SKUNF (Seikagaku) ROCE %: 0.57% (As of Mar. 2026)

What is Seikagaku ROCE %?

Seikagaku SKUNF +0.91% 72 ROCE % is 0.57% as of Mar. 2026. GuruFocus rates SKUNF with a GF Score™ of 72/100 and a GF Value™ of $17.00 (Significantly Undervalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Seikagaku's annualized ROCE % for the quarter that ended in Mar. 2026 was 0.57%.

Seikagaku (OTCPK:SKUNF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Seikagaku ROCE % Related Terms

Seikagaku ROCE % Historical Data

* Premium members only.

The historical data trend for Seikagaku's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seikagaku ROCE % Chart

Seikagaku Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

ROCE %

Get a 7-Day Free Trial

7.84

4.23

2.23

2.58

1.90

Seikagaku Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-9.48	-0.71	2.61	5.37	0.57

72GF Score

Seikagaku Corp SKUNF

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Seikagaku ROCE % Calculation

Seikagaku's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	9.573	/	( ( (562.682 - 52.993)	+	(544.13 - 47.857) )	/ 2 )
	=	9.573	/	( (509.689	+	496.273)	/ 2 )
	=	9.573	/	502.981
	=	1.90 %

Seikagaku's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	2.8	/	( ( (532.239 - 43.004)	+	(544.13 - 47.857) )	/ 2 )
	=	2.8	/	( ( 489.235	+	496.273 )	/ 2 )
	=	2.8	/	492.754
	=	0.57 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 0.57% mean?

Seikagaku (SKUNF) has a ROCE % of 0.57% as of Mar. 2026.

Is Seikagaku's ROCE % too high?

Seikagaku's current ROCE % is 0.57%. The Medical Devices & Instruments industry median ROCE % is 2.30. Seikagaku's value of 0.57% is 75.2% below this industry median. Overall, Seikagaku has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Seikagaku's ROCE % compare to ABT and SYK?

Seikagaku's ROCE % of 0.57% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.30. Seikagaku's value of 0.57% is 75.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.30, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Seikagaku's current ROCE % of 0.57% is 75.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Seikagaku's current ROCE % is 0.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Seikagaku stock overvalued right now?

Based on GuruFocus' analysis, Seikagaku (SKUNF) is currently considered Significantly Undervalued. The stock's GF Value™ is $17.00, compared to a current price of $4.44 — trading 73.9% below its estimated fair value. The current ROCE % is 0.57% and 75.2% below the Medical Devices & Instruments industry median of 2.30. Seikagaku's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Seikagaku (SKUNF), the current ROCE % is 0.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Seikagaku (SKUNF) Overvalued in 2026?

Based on GuruFocus' analysis, Seikagaku stock appears to be undervalued. The current stock price of $4.44 is trading 73.9% below its estimated GF Value™ of $17.00. GuruFocus considers Seikagaku to be Significantly Undervalued.

Key valuation signals for SKUNF:

ROCE %: 0.57%
GF Value™: $17.00 vs. price of $4.44 (73.9% below fair value)
GF Score™: 72/100 with 5 warning signs
Industry Position: 75.2% below the Medical Devices & Instruments median

No single metric tells the full story. See the SKUNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Seikagaku Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies TSE:7777 TSE:6823 TSE:7779 TSE:7600 TSE:4889 TSE:6678 TSE:7792 TSE:3079 TSE:9341 TSE:5187 ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Other Exchanges 4548:Japan

Address Marunouchi Center Building 10 Floor, 6-1, Marunouchi 1-chome, Chiyoda-ku, Tokyo, JPN, 100-0005

Website http://www.seikagaku.co.jp

Seikagaku Corp makes and sells pharmaceuticals and medical devices related to glycoconjugates. The firm operates in two segments: pharmaceutical and LAL. The pharmaceutical segment contributes the majority of revenue. This business sells pharmaceutical products made from hyaluronic acid, a major component of glycoconjugates, as well as medical devices and bulk products. The LAL segment manufactures endotoxin-detecting reagents made from limulus amebocyte lysate that are used to control quality in the pharmaceutical manufacturing process. Seikagaku generates the majority of its sales in Japan.

72GF Score

Get the complete analysis for SKUNF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.44

Price

$17.00

GF Value

View SKUNF Analysis

See ROCE % data for all stocks →